Carlo Vancheri

List of Publications by Year
in descending order

133	6,370	57631	76769
papers	citations	44 h-index	74 g-index

138	138	138	8176
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. Rheumatology, 2022, 61, 1600-1609.	0.9	53
2	Identifying the Risk of Acute Exacerbation in Idiopathic Pulmonary Fibrosis: Another Step Forward. American Journal of Respiratory and Critical Care Medicine, 2022, , .	2.5	0
3	Nintedanib in IPF: Post hoc Analysis of the Italian FIBRONET Observational Study. Respiration, 2022, 101, 577-584.	1.2	6
4	"Usual" interstitial pneumonia with autoimmune features: a prospective study on a cohort of idiopathic pulmonary fibrosis patients.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
5	A New Method for the Assessment of Myalgia in Interstitial Lung Disease: Association with Positivity for Myositis-Specific and Myositis-Associated Antibodies. Diagnostics, 2022, 12, 1139.	1.3	5
6	Clinical and radiological features of lung disorders related to connective-tissue diseases: a pictorial essay. Insights Into Imaging, 2022, 13, .	1.6	12
7	The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	1.1	22
8	Suggestions for lung function testing in the context of COVID-19. Respiratory Medicine, 2021, 177, 106292.	1.3	14
9	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. European Respiratory Review, 2021, 30, 210026.	3.0	17
10	PerFECT 2.0: A Web-Based Platform Designed to Facilitate and Support the Diagnosis of Patients with Idiopathic Pulmonary Fibrosis in Italy. Pulmonary Therapy, 2021, 7, 267-279.	1.1	0
11	Rethinking Idiopathic Pulmonary Fibrosis. Clinics in Chest Medicine, 2021, 42, 263-273.	0.8	1
12	Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2021, 38, 4040-4056.	1.3	6
13	Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association. Journal of Clinical Medicine, 2021, 10, 2548.	1.0	8
14	Quantitative Evaluation of Fibrosis in IPF Patients: Meaning of Diffuse Pulmonary Ossification. Diagnostics, 2021, 11, 113.	1.3	2
15	Outcomes and Incidence of PF-ILD According to Different Definitions in a Real-World Setting. Frontiers in Pharmacology, 2021, 12, 790204.	1.6	13
16	Assessment of Lung Cancer Development in Idiopathic Pulmonary Fibrosis Patients Using Quantitative High-Resolution Computed Tomography. Journal of Thoracic Imaging, 2020, 35, 115-122.	0.8	3
17	The Morphological Domain Does Not Affect the Rate of Progression to Defined Autoimmune Diseases in Patients With Interstitial Pneumonia With Autoimmune Features. Chest, 2020, 157, 238-242.	0.4	18
18	Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary SjÓ§gren's syndrome: A systematic review from the Italian Society of Rheumatology. Autoimmunity Reviews, 2020, 19, 102447.	2.5	59

#	Article	IF	Citations
19	Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy. Microorganisms, 2020, 8, 977.	1.6	41
20	Circulating Coding and Long Non-Coding RNAs as Potential Biomarkers of Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2020, 21, 8812.	1.8	21
21	Resumption of respiratory outpatient services in the COVID-19 era: Experience from Southern Italy. American Journal of Infection Control, 2020, 48, 1087-1089.	1.1	9
22	Multidisciplinary Approach to Interstitial Lung Diseases: Nothing Is Better than All of Us Together. Diagnostics, 2020, 10, 488.	1.3	1
23	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respiratory Medicine,the, 2020, 8, 925-934.	5.2	198
24	The Model for Early COvid-19 Recognition (MECOR) Score: A Proof-of-Concept for a Simple and Low-Cost Tool to Recognize a Possible Viral Etiology in Community-Acquired Pneumonia Patients during COVID-19 Outbreak. Diagnostics, 2020, 10, 619.	1.3	33
25	Cryptogenic Organizing Pneumonia: Evolution of Morphological Patterns Assessed by HRCT. Diagnostics, 2020, 10, 262.	1.3	21
26	Cystic Interstitial Lung Diseases: A Pictorial Review and a Practical Guide for the Radiologist. Diagnostics, 2020, 10, 346.	1.3	5
27	Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study. Respirology, 2020, 25, 1144-1151.	1.3	6
28	Stratification of long-term outcome in stable idiopathic pulmonary fibrosis by combining longitudinal computed tomography and forced vital capacity. European Radiology, 2020, 30, 2669-2679.	2.3	19
29	Nailfold Videocapillaroscopy Is a Useful Tool to Recognize Definite Forms of Systemic Sclerosis and Idiopathic Inflammatory Myositis in Interstitial Lung Disease Patients. Diagnostics, 2020, 10, 253.	1.3	14
30	Patients with Interstitial Lung Disease Secondary to Autoimmune Diseases: How to Recognize Them?. Diagnostics, 2020, 10, 208.	1.3	27
31	Morphological Patterns of Sarcoidosis and Clinical Outcome: Retrospective Analysis through a Multidisciplinary Approach. Diagnostics, 2020, 10, 212.	1.3	2
32	Quantification of Ground Glass Opacities Can Be Useful to Describe Disease Activity in Systemic Sclerosis. Diagnostics, 2020, 10, 225.	1.3	4
33	HRCT Patterns of Drug-Induced Interstitial Lung Diseases: A Review. Diagnostics, 2020, 10, 244.	1.3	27
34	Evolution and treatment of idiopathic pulmonary fibrosis. Presse Medicale, 2020, 49, 104025.	0.8	15
35	Astrocytes Modify Migration of PBMCs Induced by Î²-Amyloid in a Blood-Brain Barrier in vitro Model. Frontiers in Cellular Neuroscience, 2019, 13, 337.	1.8	15
36	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	2.5	60

#	Article	IF	Citations
37	Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 156, 78-84.	1.3	21
38	Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2019, 36, 232-243.	1.3	15
39	Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases. Multidisciplinary Respiratory Medicine, 2019, 14, 17.	0.6	43
40	Reply to: Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity!. European Respiratory Journal, 2019, 53, 1900615.	3.1	2
41	Lung CT Densitometry in Idiopathic Pulmonary Fibrosis for the Prediction of Natural Course, Severity, and Mortality. Chest, 2019, 155, 972-981.	0.4	32
42	Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients. Respiratory Medicine, 2019, 150, 154-160.	1.3	53
43	Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 54, 1901188.	3.1	9
44	Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases. BMC Pulmonary Medicine, 2019, 19, 213.	0.8	19
45	The added value of comorbidities inÂpredicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. European Respiratory Journal, 2019, 53, 1801587.	3.1	50
46	Interstitial Lung Disease in patients with Polymyalgia Rheumatica: A case series. Respiratory Medicine Case Reports, 2019, 26, 126-130.	0.2	6
47	Chest imaging using signs, symbols, and naturalistic images: a practical guide for radiologists and non-radiologists. Insights Into Imaging, 2019, 10, 114.	1.6	59
48	State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances. European Respiratory Review, 2018, 27, 170139.	3.0	47
49	Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting. Npj Primary Care Respiratory Medicine, 2018, 28, 10.	1.1	9
50	Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 356-363.	2.5	193
51	Patients with IPF and lung cancer: diagnosis and management. Lancet Respiratory Medicine,the, 2018, 6, 86-88.	5.2	67
52	Pathobiology of Novel Approaches to Treatment. , 2018, , 25-37.		0
53	Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180078.	3.0	20
54	Assessment of survival in patients with idiopathic pulmonary fibrosis using quantitative HRCT indexes. Multidisciplinary Respiratory Medicine, 2018, 13, 43.	0.6	20

#	Article	IF	Citations
55	Quantum-inspired minimum distance classification in a biomedical context. International Journal of Quantum Information, 2018, 16, 1840011.	0.6	12
56	Conditioned Media From Glial Cells Promote a Neural-Like Connexin Expression in Human Adipose-Derived Mesenchymal Stem Cells. Frontiers in Physiology, 2018, 9, 1742.	1.3	19
57	Role of imaging in progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180073.	3.0	57
58	Utility of ultrasound assessment of diaphragmatic function before and after pulmonary rehabilitation in COPD patients. International Journal of COPD, 2018, Volume 13, 3131-3139.	0.9	50
59	Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. Multidisciplinary Respiratory Medicine, 2018, 13, 39.	0.6	17
60	Comorbidities of IPF: How do they impact on prognosis. Pulmonary Pharmacology and Therapeutics, 2018, 53, 6-11.	1.1	13
61	Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 52, 1702593.	3.1	29
62	The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respiratory Research, 2018, 19, 141.	1.4	199
63	Neural differentiation of human adiposeâ€derived mesenchymal stem cells induced by glial cell conditioned media. Journal of Cellular Physiology, 2018, 233, 7091-7100.	2.0	32
64	Translation and validation of the Kingâ€™s Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch. Chronic Respiratory Disease, 2017, 14, 140-150.	1.0	19
65	Neutrophilâ€toâ€lymphocyte Ratio: An Emerging Marker Predicting Prognosis in Elderly Adults with Communityâ€Acquired Pneumonia. Journal of the American Geriatrics Society, 2017, 65, 1796-1801.	1.3	133
66	When to start and when to stop antifibrotic therapies. European Respiratory Review, 2017, 26, 170053.	3.0	39
67	Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1701157.	3.1	61
68	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75
69	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine,the, 2017, 5, 591-598.	5.2	71
70	Unmet needs in the treatment of idiopathic pulmonary fibrosisâ€•insights from patient chart review in five European countries. BMC Pulmonary Medicine, 2017, 17, 124.	0.8	77
71	Preventive and therapeutic effects of thymosin Î²4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis. Oncotarget, 2016, 7, 33841-33854.	0.8	18
72	Cough in idiopathic pulmonary fibrosis. European Respiratory Review, 2016, 25, 278-286.	3.0	82

#	Article	IF	Citations
73	New perspectives on management of idiopathic pulmonary fibrosis. Therapeutic Advances in Chronic Disease, 2016, 7, 108-120.	1.1	31
74	Qualitative European survey of patients with idiopathic pulmonary fibrosis: patientsâ€™ perspectives of the disease and treatment. BMC Pulmonary Medicine, 2016, 16, 10.	0.8	83
75	Idiopathic pulmonary fibrosis and cancer: do they really look similar?. BMC Medicine, 2015, 13, 220.	2.3	92
76	Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. BMC Medicine, 2015, 13, 277.	2.3	23
77	Idiopathic pulmonary fibrosis and lung cancer. Current Opinion in Pulmonary Medicine, 2015, 21, 626-633.	1.2	67
78	The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1426-1433.	3.1	146
79	Protein profile of exhaled breath condensate determined by high resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2015, 105, 134-149.	1.4	32
80	Idiopathic pulmonary fibrosis: An update. Annals of Medicine, 2015, 47, 15-27.	1.5	97
81	Effects of thymosin Î²4 and its N-terminal fragment Ac-SDKP on TGF-Î²-treated human lung fibroblasts and in the mouse model of bleomycin-induced lung fibrosis. Expert Opinion on Biological Therapy, 2015, 15, 211-221.	1.4	16
82	Anti-inflammatory and antifibrotic effects of resveratrol in the lung. Histology and Histopathology, 2015, 30, 523-9.	0.5	29
83	IPF, comorbidities and management implications. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32 Suppl 1, 17-23.	0.2	8
84	Altered Surfactant Homeostasis and Alveolar Epithelial Cell Stress in Amiodarone-Induced Lung Fibrosis. Toxicological Sciences, 2014, 142, 285-297.	1.4	40
85	Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respiratory Medicine,the, 2014, 2, 933-942.	5.2	128
86	Thymosin Î²4 reduces IL-17-producing cells and IL-17 expression, and protects lungs from damage in bleomycin-treated mice. Immunobiology, 2014, 219, 425-431.	0.8	23
87	Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events. Advances in Therapy, 2014, 31, 375-391.	1.3	115
88	Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): a pictorial review. Insights Into Imaging, 2014, 5, 347-364.	1.6	42
89	Effect of pirfenidone on proliferation, TGF-Î²-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. European Journal of Pharmaceutical Sciences, 2014, 58, 13-19.	1.9	281
90	PI3K p110Î³ overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition. Laboratory Investigation, 2013, 93, 566-576.	1.7	74

#	Article	IF	Citations
91	Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and organ donors. Journal of Proteomics, 2013, 85, 109-128.	1.2	64
92	Human lung fibroblasts increase CD4(+)CD25(+)Foxp3(+) T cells in co-cultured CD4(+) lymphocytes. Cellular Immunology, 2013, 285, 55-61.	1.4	4
93	Differentiation of human adipose stem cells into neural phenotype by neuroblastomaâ€•or olfactory ensheathing cellsâ€conditioned medium. Journal of Cellular Physiology, 2013, 228, 2109-2118.	2.0	29
94	A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. European Respiratory Journal, 2013, 41, 262-269.	3.1	71
95	Common pathways in idiopathic pulmonary fibrosis and cancer. European Respiratory Review, 2013, 22, 265-272.	3.0	143
96	Thymosin Î²4 protects <scp>C</scp>57<scp>BL</scp>/6 mice from bleomycinâ€induced damage in the lung. European Journal of Clinical Investigation, 2013, 43, 309-315.	1.7	28
97	Idiopathic Pulmonary Fibrosis. Proceedings of the American Thoracic Society, 2012, 9, 153-157.	3.5	55
98	Protective effects of thymosin Î²4 in a mouse model of lung fibrosis. Annals of the New York Academy of Sciences, 2012, 1269, 69-73.	1.8	17
99	Resveratrol inhibits transforming growth factor-Î²â€“induced proliferation and differentiation of ex vivo human lung fibroblasts into myofibroblasts through ERK/Akt inhibition and PTEN restoration. Experimental Lung Research, 2011, 37, 162-174.	0.5	50
100	Inhibition of PI3K Prevents the Proliferation and Differentiation of Human Lung Fibroblasts into Myofibroblasts: The Role of Class I P110 Isoforms. PLoS ONE, 2011, 6, e24663.	1.1	126
101	Reactive Oxygen Species Are Required for Maintenance and Differentiation of Primary Lung Fibroblasts in Idiopathic Pulmonary Fibrosis. PLoS ONE, 2010, 5, e14003.	1.1	122
102	Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. European Respiratory Journal, 2010, 35, 496-504.	3.1	399
103	Antiproliferative effects induced by guanine-based purines require hypoxanthine-guanine phosphoribosyltransferase activity. Biological Chemistry, 2010, 391, 1079-89.	1.2	8
104	Acute additive effect of montelukast and beclomethasone on AMP induced bronchoconstriction. Respiratory Medicine, 2010, 104, 1417-1424.	1.3	4
105	16,16-Dimethyl Prostaglandin E2Efficacy on Prevention and Protection from Bleomycin-Induced Lung Injury and Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 50-58.	1.4	32
106	TGF-Î²1 targets the GSK-3Î²/Î²-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacological Research, 2008, 57, 274-282.	3.1	180
107	Subsegmental Pulmonary Embolism: Value of Thoracic Ultrasound for Diagnosis and Follow-Up. Internal Medicine, 2008, 47, 1415-1417.	0.3	9
108	Protective effect of orally administered carnosine on bleomycin-induced lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L1095-L1104.	1.3	63

#	Article	IF	Citations
109	Exhaled bronchial cysteinyl leukotrienes in allergic patients. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 25-31.	1.1	6
110	Activation of cytosolic phospholipase A2 and 15-lipoxygenase by oxidized low-density lipoproteins in cultured human lung fibroblasts. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 522-532.	1.2	16
111	Astrocyte-like cells as a main target for estrogen action during neuronal differentiation. Molecular and Cellular Neurosciences, 2007, 34, 562-570.	1.0	9
112	Effects of TGF-Î² and glucocorticoids on map kinase phosphorylation, IL-6/IL-11 secretion and cell proliferation in primary cultures of human lung fibroblasts. Journal of Cellular Physiology, 2007, 210, 489-497.	2.0	50
113	Altered intercellular communication in lung fibroblast cultures from patients with idiopathic pulmonary fibrosis. Respiratory Research, 2006, 7, 122.	1.4	47
114	Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respiratory Research, 2006, 7, 137.	1.4	40
115	Endothelin-1 induces proliferation of human lung fibroblasts and IL-11 secretion through an ETA receptor-dependent activation of map kinases. Journal of Cellular Biochemistry, 2005, 96, 858-868.	1.2	48
116	The p53-homologue p63 may promote thyroid cancer progression. Endocrine-Related Cancer, 2005, 12, 953-971.	1.6	50
117	Interaction between human lung fibroblasts and T-lymphocytes prevents activation of CD4+ cells. Respiratory Research, 2005, 6, 103.	1.4	19
118	Inhibition or knock out of Inducible nitric oxide synthase result in resistance to bleomycin-induced lung injury. Respiratory Research, 2005, 6, 58.	1.4	60
119	Montelukast protects against bradykinin-induced bronchospasm. Journal of Allergy and Clinical Immunology, 2005, 115, 870-872.	1.5	11
120	Bradykinin differentiates human lung fibroblasts to a myofibroblast phenotype via the B2 receptor. Journal of Allergy and Clinical Immunology, 2005, 116, 1242-1248.	1.5	37
121	Bradykinin and Tachykinin-induced Leukotriene Release in Airway Virus Infections. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 511-511.	2.5	1
122	The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. Allergy and Asthma Proceedings, 2005, 26, 292-8.	1.0	9
123	Î²-Amyloid-Activated Cell Cycle in SH-SY5Y Neuroblastoma Cells: Correlation with the MAP Kinase Pathway. Journal of Molecular Neuroscience, 2004, 22, 231-236.	1.1	27
124	The lung as a privileged site for the beneficial actions of PGE2. Trends in Immunology, 2004, 25, 40-46.	2.9	284
125	Impact of intranasal budesonide on immune inflammatory responses and epithelial remodeling in chronic upper airway inflammation. Journal of Allergy and Clinical Immunology, 2003, 112, 37-44.	1.5	40
126	Inhibitory effect of a leukotriene receptor antagonist (montelukast) on neurokinin a-induced bronchoconstriction. Journal of Allergy and Clinical Immunology, 2003, 111, 833-839.	1.5	24

#	Article	IF	Citations
127	Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2001, 108, 703-708.	1.5	63
128	Normal Human Lung Fibroblasts Differently Modulate Interleukin-10 and Interleukin-12 Production by Monocytes. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 592-599.	1.4	36
129	Different Expression of TNF- Î± Receptors and Prostaglandin E₂Production in Normal and Fibrotic Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 628-634.	1.4	89
130	Nuclear factor-ÎºB activation in human monocytes stimulated with lipopolysaccharide is inhibited by fibroblast conditioned medium and exogenous PGE2. FEBS Letters, 1997, 400, 315-318.	1.3	18
131	Release of Mast-Cell-derived Mediators after Endobronchial Adenosine Challenge in Asthma. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 624-629.	2.5	153
132	Human Upper Airway Epithelial Cell-Derived Granulocyte-Macrophage Colony-Stimulating Factor Induces Histamine-Containing Cell Differentiation of Human Progenitor Cells. International Archives of Allergy and Immunology, 1991, 95, 376-384.	0.9	34
133	"Usual" interstitial pneumonia with autoimmune features: a prospective study on a cohort of idiopathic pulmonary fibrosis patients. Clinical and Experimental Rheumatology, 0, , .	0.4	5